Enabling Powerful POC and Mobile Diagnostics
LamdaGen Corporation is a privately held developer of nano-based biosensors and powerful testing systems. The Company’s core diagnostic technology is a quantitative immuno-based platform that combines the high sensitivity of an ELISA with the simplicity and speed of LFA to enable quantitative detection of diseases, pathogens and contaminants.
There is a global need for advanced technologies that enable highly sensitive and quantitative detection to provide precise results at point of use in ~15 minutes.
To meet this need, LamdaGen has developed L’AuRa – a category-defining digital testing platform that enables significant performance and use advantages vs multi-hour ELISA’s and Lateral Flow assays.
LamdaGen’s L’AuRa digital technology enables robust diagnostic systems that are simple, compact and cost effective. L’AuRa’s flexible designs range from miniaturized handhelds to small desktops to lab-based throughput systems – each providing powerful on the spot performance including – rapid fifteen minute quantitative assays with LOQ’s into the low pg/mL or parts per trillion (PPT) range*
LamdaGen licenses its sensing technologies on an open-source basis to companies in the following sectors.